Kiniksa Pharmaceuticals International (KNSA) Cash from Operations (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Cash from Operations for 10 years, with the latest figure at 50199000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 124.87% year-over-year to 50199000.0; the trailing twelve-month figure through Mar 2026 stood at 165860000.0 (up 276.73% YoY), and the FY2025 full-year result was 137985000.0, up 437.14% from the prior year.
• Cash from Operations for Q1 2026 stood at 50199000.0, down from 53894000.0 in the prior quarter.
• The five-year high for Cash from Operations was 62053000.0 in Q3 2022, with the low at 36846000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 13704764.71 across 5 years, with a median of 5168000.0 in 2024.
• Annual changes were most pronounced in 2024 — Cash from Operations plunged 113.16% — and 2025, when it jumped 1606.13%.
• Kiniksa Pharmaceuticals International's Cash from Operations stood at 11576000.0 in 2022, then surged by 137.36% to 4325000.0 in 2023, then soared by 333.99% to 18770000.0 in 2024, then surged by 187.13% to 53894000.0 in 2025, then slipped by 6.86% to 50199000.0 in 2026.
• The last three Cash from Operations figures came in at 50199000.0 (Q1 2026), 53894000.0 (Q4 2025), and 33677000.0 (Q3 2025), per Business Quant data.